Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL).

被引：3
|
作者：
Schilder, RJ
Witzig, TE
Flinn, I
Gordon, LI
Emmanouilides, C
Wang, H
Vo, K
Molina, A
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Mayo Clin, Dept Hematol Oncol, Rochester, MN USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA
[4] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA 90024 USA
[6] Biogen Idec Inc, Global Med Affairs, San Diego, CA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2629.2629
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2629
引用
收藏
页码：719A / 719A
页数：1
相关论文
共 50 条
  • [1] Long-term responses in patients with relapsed or refractory follicular lymphoma treated with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Macklis, R
    Molina, A
    Pohlman, B
    Gordon, L
    Wang, H
    Saville, MW
    Witzig, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S542 - S543
  • [2] Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Rodriguez, MA
    Romaguera, JE
    McLaughlin, P
    Wang, M
    Hagemeister, FB
    Dang, NH
    Neelapu, S
    Podoloff, D
    BLOOD, 2005, 106 (11) : 689A - 690A
  • [3] A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)
    Younes, A
    Rodriguez, M
    Pro, B
    McLaughlin, P
    Romaguera, J
    Hagemeister, F
    Wang, M
    ANNALS OF ONCOLOGY, 2005, 16 : 96 - 96
  • [4] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Oki, Y
    Pro, B
    Delpassand, E
    Ballaster, V
    McLaughlin, P
    Romaguera, J
    Wang, M
    Hagemeister, FB
    Younes, A
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [5] Yttriutm-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) : 185 - 188
  • [6] RADIOIMMUNOTHERAPY OF (90Y)-IBRITUMOMAB TIUXETAN FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA
    Yoshida, Isao
    Kogure, Yuuki
    Kajihara, Makoto
    ANNALS OF ONCOLOGY, 2014, 25
  • [7] Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma
    Demeter, J.
    Balassa, K.
    Domotor, M.
    Egyed, M.
    Gasztonyi, Z.
    Aryab, H.
    Gurzo, M.
    Ivayi, J.
    Klucsik, Zs.
    Sreter, L.
    Nagy, Zs.
    BLOOD REVIEWS, 2007, 21 : S138 - S139
  • [8] Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin)
    Gregory, SA
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 17 - 22
  • [9] FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma
    Lopci, E.
    Santi, I.
    Tani, M.
    Maffione, A. M.
    Montini, G.
    Castellucci, P.
    Stefoni, V.
    Rubello, D.
    Fonti, C.
    Zinzani, P.
    Fanti, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (04): : 436 - 441
  • [10] Phase II study of Yttrium 90 (90Y) lbritumomab tiuxetan (Zevalin®) in patients with relapsed and refractory mantle cell lymphoma (MCL).
    Wang, Michael
    Oki, Yasuhiro
    Pro, Barbara
    Romaguera, Jorge Enrique
    Rodriguez, Maria Alma
    Samaniego, Felipe
    McLaughlin, Peter
    Hagemeister, Frederick
    Neelapu, Sattva
    Podoloff, Donald
    Samuels, Barry
    Loyer, Evelyne
    Zhou, Yuhong
    Younes, Anas
    BLOOD, 2006, 108 (11) : 767A - 767A
12345